|
Nov 9
|
Roche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation
|
|
Nov 7
|
Q3 2023 Halozyme Therapeutics Inc Earnings Call
|
|
Nov 7
|
Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag
|
|
Nov 7
|
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call Transcript
|
|
Nov 6
|
Roche Sells $5.5 Billion of Bonds to Fund Telavant Buyout
|
|
Nov 6
|
Individual investors account for 55% of Roche Holding AG's (VTX:ROG) ownership, while institutions account for 36%
|
|
Nov 3
|
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues
|
|
Nov 2
|
Sarepta (SRPT) Q3 Loss Narrower Than Expected, Sales Beat
|
|
Sep 28
|
Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs
|
|
Sep 24
|
Are Roche Holding AG's (VTX:ROG) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
|
|
Aug 11
|
Q2 2023 Lineage Cell Therapeutics Inc Earnings Call
|
|
Aug 9
|
Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised
|
|
Aug 8
|
New opportunities and persistent challenges revealed as organisations attempt more data-driven approaches to healthcare, says new report from Harvard Business Review Analytic Services
|